Complementary in vivo assays substantiate that RP-6306, either as monotherapy or in synergy with gemcitabine, significantly escalates CD86 levels while diminishing CD163 expression in tumor matrices (Figs. 4G, 6I, S3A, B). Here, CD163 is linked to neoplasm.